Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors
jRCT2041250015Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- May 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of SGN-PDL1V and pembrolizumab in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC) and 4 more (2 arms), sponsored by Pfizer. Primary endpoints: Number of participants with adverse events (AEs), Number of participants with laboratory abnormalities and 2 more. Started May 2025; status: recruiting.
02
Drugs
SGN-PDL1Vpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)triple-negative breast cancer (TNBC)ovarian cancer
Beyond the preview
Go deeper on jRCT2041250015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250015.